Pfizer and German Merck can breathe a sigh of relief after a phase 3 trial confirmed that their immunotherapy Bavencio produces a survival benefit in bladder cancer, when used as a maintena
Patients in England are to get easier access to Merck KGaA’s multiple sclerosis drug Mavenclad after NICE dropped requirements for a special MRI scan before prescription.
The FDA thinks German Merck could have a breakthrough in its hands with a new lung cancer drug that targets aggressive tumours with a mutation known as MET.
With Merck KGaA’s multiple sclerosis drug evobrutinib entering phase 3 trials, we spoke to the company’s Fernando Dangond and MS expert Dr Xavier Montalban to get their views on the biggest
